Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India
BLOOD CELL THERAPY / The official journal of APBMT · 2026 · 9 (2)
DOI: 10.31547/bct-2025-029 ↗Kurz gefasst
Fachartikel in der Zeitschrift BLOOD CELL THERAPY / The official journal of APBMT, 2026. Verfasst von Nishant Jindal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Outcomes of haploidentical transplantation have been reported to be comparable to HLA-matched transplants in several studies; however, data from low- and middle-income countries remain limited. In this retrospective study, we evaluated outcomes of 71 patients who underwent haploidentical transplantation for malignant indications using post-transplant cyclophosphamide (PTCy) between July 2010 and March 2022 and analyzed donor factors influencing outcomes. All patients received peripheral blood stem cell grafts with standard PTCy/calcineurin inhibitor/mycophenolate mofetil prophylaxis. Graft failure occurred in seven patients (9.8%), with a higher incidence observed in those with 0-1 mismatch in the graft versus host direction (p=0.011). The incidences of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD were 42.3% and 47.7%, respectively. Overall transplant related mortality (TRM) was 42.3%. Donor killer-cell immunoglobulin-like receptor haplotype BX with 2DS2 and the Bw6Bw6 ligand in recipients were associated with a reduced risk of relapse. The 5-year overall survival was 31.9%. On multivariate analysis, female donors were associated with improved overall survival (hazard ratio 0.465 [95% confidence interval 0.222-0.974], p=0.042). Transplant outcomes were primarily limited by a high incidence of TRM. These findings warrant validation in larger multicenter studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
- Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, India.
- Transplant Immunology and Immunogenetics Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
- Epidemiology and Clinical Trials Unit, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi, Mumbai, India.
Zitieren
APA
Jindal, N., Gokarn, A., Garg, M., Kumbhalwar, K., D Silva, S., Singh, M., Kannan, S., Jacob Mathew, L., Mirgh, S., Chichra, A., Nayak, L., Bonda, A., Punatar, S., Bagal, B., & Khattry, N. (2026). Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India. BLOOD CELL THERAPY / The official journal of APBMT, 9(2). https://doi.org/10.31547/bct-2025-029
Vancouver
Jindal N, Gokarn A, Garg M, Kumbhalwar K, D Silva S, Singh M, et al. Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India. BLOOD CELL THERAPY / The official journal of APBMT. 2026;9(2). doi:10.31547/bct-2025-029
BibTeX
@article{Jindal2026,
author = {Jindal, Nishant and Gokarn, Anant and Garg, Malini and Kumbhalwar, Komal and D Silva, Selma and Singh, Meenakshi and Kannan, Sadhana and Jacob Mathew, Libin and Mirgh, Sumeet and Chichra, Akanksha and Nayak, Lingaraj and Bonda, Avinash and Punatar, Sachin and Bagal, Bhausaheb and Khattry, Navin},
title = {Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India},
journal = {BLOOD CELL THERAPY / The official journal of APBMT},
year = {2026},
volume = {9},
number = {2},
doi = {10.31547/bct-2025-029}
}
EUVIMED